Rigel Pharmaceuticals (RIGL) Other financing activities (2018 - 2025)
Rigel Pharmaceuticals' quarterly Other financing activities came in at $4.3 million in Q3 2025, up 2603.16% year-on-year from $158000.0 in Q3 2024, and up 921.77% quarter-over-quarter from $418000.0 in Q2 2025.
Rigel Pharmaceuticals has reported Other financing activities for 8 years, with the latest figure at $4.3 million in Q3 2025.
- For the quarter ending Q3 2025, Other financing activities rose 2603.16% year-over-year to $4.3 million; the trailing twelve-month figure through Sep 2025 stood at $6.6 million (up 573.91% YoY), and the FY2024 full-year result was $2.0 million, up 87.23% from the prior year.
- Other financing activities for Q3 2025 stood at $4.3 million, up from $418000.0 in the prior quarter.
- The five-year high for Other financing activities was $4.3 million in Q3 2025, with the low at $1000.0 in Q1 2023.
- Average Other financing activities over 5 years is $852941.2, with a median of $486000.0 recorded in 2023.
- Year-over-year, Other financing activities tumbled 99.89% in 2023 and soared 8800.0% in 2024.
- Tracing RIGL's Other financing activities over 5 years: stood at $1.1 million in 2021, then plunged by 44.79% to $599000.0 in 2022, then retreated by 18.86% to $486000.0 in 2023, then soared by 201.44% to $1.5 million in 2024, then soared by 191.54% to $4.3 million in 2025.
- The last three Other financing activities figures came in at $4.3 million (Q3 2025), $418000.0 (Q2 2025), and $484000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 418,000.00 |
| Jun 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 158,000.00 |
| Sep 30, 2024 | 158,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 486,000.00 |
| Dec 31, 2023 | 486,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 554,000.00 |
| Jun 30, 2023 | 554,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Jun 30, 2022 | 599,000.00 |
| Jun 30, 2022 | 599,000.00 |
| Mar 31, 2022 | 940,000.00 |
| Mar 31, 2022 | 940,000.00 |
| Dec 31, 2021 | 1.09 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Sep 30, 2021 | 274,000.00 |
| Sep 30, 2021 | 274,000.00 |
| Jun 30, 2021 | 1.32 Mn |
| Jun 30, 2021 | 1.32 Mn |
| Mar 31, 2021 | 2.10 Mn |
| Mar 31, 2021 | 2.10 Mn |
| Dec 31, 2020 | 667,000.00 |
| Dec 31, 2020 | 667,000.00 |
| Sep 30, 2020 | 52,000.00 |
| Sep 30, 2020 | 52,000.00 |
| Jun 30, 2020 | 541,000.00 |
| Jun 30, 2020 | 541,000.00 |
| Mar 31, 2020 | 1.34 Mn |
| Mar 31, 2020 | 1.34 Mn |
| Dec 31, 2019 | 695,000.00 |
| Dec 31, 2019 | 695,000.00 |
| Sep 30, 2019 | 9,000.00 |
| Sep 30, 2019 | 9,000.00 |
| Jun 30, 2019 | 856,000.00 |
| Jun 30, 2019 | 856,000.00 |
| Mar 31, 2019 | 16,000.00 |
| Mar 31, 2019 | 16,000.00 |
| Dec 31, 2018 | -66.06 Mn |
| Dec 31, 2018 | -66.06 Mn |
| Sep 30, 2018 | 635,000.00 |
| Sep 30, 2018 | 635,000.00 |
| Jun 30, 2018 | 68.15 Mn |
| Jun 30, 2018 | 68.15 Mn |
| Mar 31, 2018 | 2.01 Mn |
| Mar 31, 2018 | 2.01 Mn |